Immunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review

Area of Science:

• Oncology and Immunology
• Cancer Therapeutics
• Personalized Medicine

Background:

• Prostate cancer (PCa) is a leading cause of cancer death globally, with limited options for advanced stages.
• Early immunotherapies faced challenges due to poor tumor infiltration and immunosuppression.
• Current treatments include hormonal therapy, radiation, surgery, and chemotherapy, with immunotherapy emerging as a key area.

Purpose of the Study:

• To review the current landscape of prostate cancer immunotherapy.
• To analyze established treatment guidelines (NCCN, EANM-ESTRO-ESUR-ISUP-SIOG).
• To examine immunotherapeutic strategies including immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT).

Main Methods:

• Comprehensive review of current and investigational immunotherapies for prostate cancer.
• Analysis of treatment guidelines and clinical trial data.
• Focus on ICIs, CAR T-cell therapy, combination approaches, and predictive biomarkers.

Main Results:

• Immunotherapy strategies like ICIs and ACT (including CAR T-cells) are advancing, particularly for metastatic castration-resistant prostate cancer (mCRPC).
• Personalized medicine and combination therapies are crucial due to tumor heterogeneity and variable patient responses.
• Predictive biomarkers are essential for optimizing immunotherapy efficacy.

Conclusions:

• Immunotherapy holds significant potential for prostate cancer management, especially in advanced stages.
• Further research into combination therapies, CAR T-cell strategies, and predictive biomarkers is needed.
• Addressing challenges in immunotherapy implementation is vital for future clinical success.